Enobia testing drug for rare genetic disease

Canada's Enobia Pharma has been testing a new drug designed to fight hypophosphatasia, a rare genetic disease that causes bone disorders in adults and rickets in children. Researchers say the disease only occurs in one out of every 100,000 people and is most prevalent in the Mennonite community in Manitoba. Enobia is conducting the trial at three sites around the world. One of those sites is Winnipeg's Health Sciences Centre, where a 10-month-old patient from Northern Ireland is being treated. The child, Amy Tinsley, is reportedly responding well so far.

- read the story from the Winnipeg Free Press

Suggested Articles

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.